News

Joining Medtronic are Ardian’s three existing investors: Advanced Technology Ventures, Morgenthaler Ventures and Split Rock Partners, as well as new investor Emergent Medical Partners. Andrew Cleeland, president and

Under the agreement, clinical laboratory customers around the world continue to have access to the largest portfolio of coagulation instruments and tests. The companies will also continue joint

BioDuro will provide integrated research services in the areas of discovery chemistry, discovery biology, ADMET, and DMPK services, to help enhance internal drug discovery and shorten development timelines.

The study is a randomized, double-blind, placebo-controlled study in approximately 140 patients to evaluate the safety, tolerability and efficacy of daily TT-223 treatments in combination with weekly administrations

BioMarin Pharmaceutical has reported that its clinical trial application, or CTA, for BMN 110 or N-acetylgalactosamine 6-sulfatase, intended for the treatment of the lysosomal storage disorder mucopolysaccharidosis type

According to the company, the Therakos Cellex photopheresis system is an easy-to-use, integrated system that uses extracorporeal photopheresis, a cellular therapy, to relieve the symptoms of cutaneous T-cell

The new company, headquartered in Deerfield, Illinois, will focus on acquiring and operating specialty pharmaceutical companies and products. Target opportunities include products which are already approved or currently

ACell’s MatriStem regenerative medicine technology is a naturally occurring bioscaffold derived from porcine tissue. When MatriStem is placed onto a wound, it is resorbed and replaced with new

This study follows on positive outcomes in the Phase I study assessing the safety, pharmacokinetics and efficacy of the combination. The Phase II Advance trial will assess NPI-2358